#USA #Tampa #neuroplastogens #Psilera #PSIL-006

Psilera's Fall Conference Schedule: Showcasing Innovations in Neuroplastogens

Psilera Inc., a pioneering biopharmaceutical firm known for its breakthroughs in neuroplastogens and psychedelic therapies, has just rolled out its exciting fall conference schedule. As the company gears up to share its latest innovations, key executives will be making appearances at significant biopharma and neuroscience events across the country.

Upcoming Conferences

1. 9th Annual Neuropsychiatric Drug Development Summit

Dates: September 15 - 17
Location: Boston, MA
At this event, Dr. Magali Haas, the Chief Medical Officer of Psilera, will engage in a featured panel titled "To What Degree Does Neuroplasticity Underpin Psychedelics Efficacy?" Joining her is Dr. Jackie von Salm, the Co-Founder and Chief Scientific Officer, who will contribute insights into the evolving landscape of neuroplasticity in therapeutic settings.

2. 15th International Conference on Frontotemporal Dementias (ISFTD)

Dates: October 8 - 11
Location: Philadelphia, PA
Psilera will be represented by Scott Rairigh, EVP of Corporate Development, along with Dr. Haas. Their objective is to foster collaborations with top clinical researchers and patient advocacy groups while highlighting the therapeutic potential of PSIL-006 and its role in tackling neurodegenerative diseases, particularly frontotemporal dementia (FTD).

3. University of Wisconsin-Madison Psychedelic Symposium

Dates: October 29 - 30
Location: Fitchburg, WI
Scott Rairigh will also participate in this symposium, engaging with researchers, students, and industry stakeholders to exchange the latest research findings and promote collaboration within this fast-evolving field.

4. Jefferies HealthCare Week

Dates: November 16 - 19
Location: London
Co-founders Chris Witowski and Dr. Jackie von Salm will hold discussions with potential development partners and investors in Europe. This represents a pivotal opportunity to advance the PSIL-006 clinical program further.

Opportunities for Engagement

Psilera's leadership is keen on making connections with investors and partners at these conferences. Interested parties can schedule one-on-one meetings during these events by reaching out to Psilera through their contact information provided on their official website.

About Psilera

Psilera is setting new benchmarks in the field of mental health. The company is at the forefront of developing innovative psychedelics and neuroplastogens, boasting a strong pipeline of exclusive therapeutics. Their flagship product, PSIL-006, stands out as a first-in-class therapy aimed at delivering the neuroplastic benefits associated with traditional psychedelics while minimizing hallucinogenic side effects. With a commitment to scientific excellence and an ambition to enhance the patient journey, Psilera is truly leading a new era in neuroscience. For more information about their breakthroughs and vision, visit www.psilera.com.